Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Language: | English |
Published: |
American Society of Clinical Oncology
2020
|